E H A / Education / ESH-EHA Scientific Workshops / WORKSHOP MOLECULAR PROGNOSTIC MARKERS OCTOBER 2008
WORKSHOP MOLECULAR PROGNOSTIC MARKERS OCTOBER 2008
ESH-EHA Scientific workshop, Mandelieu, Cannes (France)
Molecular Prognostic Markers in Acute Myeloid Leukemia
3 - 5 October, 2008
The identification of molecular genetic changes such as gene mutations or deregulated gene expression has greatly advanced our understanding of the pathogenesis of acute myeloid leukemia (AML). These markers now allow us to dissect the enormous heterogeneity that is seen within cytogenetically defined subgroups of AML. In part, these markers have been shown to be of great prognostic implication. Furthermore, these genetic changes are providing targets for molecular therapeutic approaches. In this workshop, leading experts in the field will review current knowledge and present the latest developments on the pathogenesis and clinical impact of biomarkers as well as data on new molecular alterations derived from innovative genomics technologies.
If you would be interested in taking part as a participant, please visit www.esh.org/agenda08.htm to register on line and to book your hotelaccommodation. You are also welcome to contact EHA: education@ehaweb.org or ESH: marie-france.simon@univ-paris-diderot.fr for any supplementary information.
|
Friday, October 3 |
||
|
10:00-10:15 |
Welcome |
|
|
Session 1 |
Gene Mutations |
|
|
CEBPA: Biology and Prognostic significance |
H. Dombret |
|
|
NPM1:Biology and prognostic significance |
B. Falini |
|
|
NPM1:Prognostic significance |
K. Döhner |
|
|
NPM1:Therapeutic targeting |
R. Schlenk |
|
|
FLT3: Prognostic significance |
R. Gale |
|
|
FLT3: Prognostic significance allelic ratio |
C. Thiede |
|
|
FLT3: Therapeutic targeting |
D. Small |
|
|
Round Table |
||
|
Session 2 |
Gene Mutations (continued) |
|
|
KIT mutations |
P. Paschka |
|
|
WT1 mutations |
J. Fitzgibbon |
|
|
MLL-PTD |
S. Whitman |
|
|
AML1 mutations |
S. Schnittger |
|
|
Round Table |
||
|
Session 3 |
Prognostic Impact of Cytogenetics: New Insights Revisited |
|
|
Individual cytogenetic markers |
C. Bloomfield |
|
|
Individual cytogenetic markers |
B. Lowenberg |
|
|
Individual cytogenetic markers |
D. Grimwade |
|
|
Round Table |
||
|
Saturday, October 4 |
||
|
Session 4 |
SNP Analyses |
|
|
SNP in AML |
J. Downing |
|
|
SNP in AML |
B. Young |
|
|
SNP in AML |
N.N. |
|
|
Round Table |
||
|
Session 5 |
Gene Expression |
|
|
BAALC: Biology and prognostic significance |
C. Baldus |
|
|
EVI-1: Biology and prognostic significance |
R. Delwel |
|
|
ERG: Biology and prognostic significance |
G. Marcucci |
|
|
MN1: Biology and prognostic significance |
A. Ganser |
|
|
Round Table |
||
|
Session 6 |
High Throughput Technologies |
|
|
Gene expression profilling |
P. Valk |
|
|
Gene expression profilling |
L. Bullinger |
|
|
Gene expression profilling |
T. Haferlach |
|
|
Gene expression profilling |
M. Radmacher |
|
|
MicroRNA profiling |
T. Golub |
|
|
MicroRNA profiling |
M. Jongen |
|
|
Round Table |
||
|
Sunday, October 5 |
||
|
Session 7 |
Towards an Integrated Prognostic Algorithm |
|
|
Considerations about a composite prognostic score |
S. Amadori |
|
|
Considerations about a composite prognostic score |
F. Appelbaum |
|
|
Considerations about a composite prognostic score |
C. Bloomfield |
|
|
Considerations about a composite prognostic score |
A. Burnett |
|
|
Considerations about a composite prognostic score |
H. Dohner |
|
|
Considerations about a composite prognostic score |
H. Dombret |
|
|
Considerations about a composite prognostic score |
E. Estey |
|
|
Considerations about a composite prognostic score |
B. Lowenberg |
|
|
Considerations about a composite prognostic score |
T. Naoe |
|
|
Considerations about a composite prognostic score |
J. Sierra |
|
|
Considerations about a composite prognostic score |
M. Tallman |
|
|
Open forum: Conclusions, Recommendations |
Tip a colleague ] [
Print view ]
Last updated on Tuesday 04 March 2008.
